WJ35435 is a dual-targeting anticancer agent with potential applications in cancer research, exhibiting inhibitory activity against histone deacetylases (particularly HDAC1 and HDAC6) and topoisomerase I. It induces DNA damage, impairs DNA repair capacity, causes cell cycle arrest at G1 and G2 phases, and ultimately triggers apoptosis.